肺癌患者血浆中基质金属蛋白酶抑制剂2蛋白水平及其临床意义

目的： 检测基质金属蛋白酶抑制剂2 (tissue inhibitor of metalloproteinases 2，TIMP2)在肺癌患者血浆中的蛋白水平及其临床意义。方法：通过对214例血浆样本，包括114例肺癌患者、100例健康人，采用酶联免疫吸附试验 (enzyme linked immunosorbent assay，ELISA)进行检测，测定TIMP2蛋白的血浆浓度，检验其诊断肺癌的敏感性和特异性。结果：ELISA检测结果显示，肺癌患者血浆中TIMP2蛋白浓度为 (74.56±16.70) ng/mL，显著低于正常对照人群 (170.98±48.61) ng/mL (P<0.01)。且TIMP2蛋白在晚期 (Ⅲ+Ⅳ期)肺癌患者血浆中的水平 (81.57±15.62) ng/mL显著高于早期 (Ⅰ+Ⅱ期)肺癌患者 (69.16±15.63) ng/mL (P<0.01)；在肿瘤直径小于或等于3 cm肺癌患者血浆中TIMP2蛋白水平显著低于肿瘤直径大于3 cm的肺癌患者 (P<0.01)，并且与肺癌的远处转移相关 (P<0.01)。当cutoff值定为103.29 ng/mL时，TIMP2检测肺癌的敏感性为97.4%，特异性为82.8%。结论：检测血浆中TIMP2的蛋白水平有助于肺癌的诊断。

TIMP2 plasma protein level and its clinical significance in lung cancer patients

OBJECTIVE: To detect the plasma protein levels of tissue inhibitor of metalloproteinases 2 (TIMP2) in lung cancer patients and healthy controls，and analyze its clinical significance. METHODS：Plasma TIMP2 level in 114 patients with primary lung cancer and 100 healthy subjects were measured by an enzyme immunoassay (ELISA). RESULTS：The plasma level of TIMP2 in patients with primary lung cancer (74.56±16.70) ng/mL was significantly lower than the healthy controls (170.98±48.61) ng/mL (P<0.01). The TIMP2 level in stage Ⅲ+Ⅳ(81.57±15.62) ng/mL were significantly higher than those in stage Ⅰ+Ⅱ(69.16±15.63) ng/mL (P<0.01). The plasma TIMP2 levels were elevated in the patients with tumor >3 cm (P<0.01)，and correlated with distant metastasis (P<0.01). When the TIMP2 cutoff value was set to 103.29 ng/mL，sensitivity of lung cancer detection was 97.4%， and specificity was 82.8%. CONCLUSION：Measurement of plasma level of TIMP2 protein may contribute to the diagnosis of lung cancer.